The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

(2012) M. Reck   ANNALS OF ONCOLOGY

Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

(2012) Raffaele Califano et al.   DRUGS

Circulating MicroRNAs: Possible Prediction Biomarkers for Personalized Therapy of Non–Small-Cell Lung Carcinoma

(2011) Wen Gao et al.   Clinical Lung Cancer

De novo discovery of mutated driver pathways in cancer

(2011) F. Vandin et al.   GENOME RESEARCH

HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer

(2011) Aifen Lin et al.   LUNG CANCER

Genetic and epigenetic changes in lung carcinoma and their clinical implications

(2011) Jing Wen et al.   MODERN PATHOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression

(2010) Tetsuro Baba et al.   CANCER SCIENCE

Staging of non-small cell lung cancer (NSCLC): A review

(2010) S. Tsim et al.   RESPIRATORY MEDICINE

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis

(2008) João Paulo da Silveira Nogueira Lima et al.   EUROPEAN JOURNAL OF CANCER

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION